Literature DB >> 8256560

Low frequency of post-lumbar puncture headache in demented patients.

K Blennow1, A Wallin, O Häger.   

Abstract

The frequency of post-lumbar puncture headache (PLPH) was registered prospectively in 395 consecutive demented patients at a dementia diagnostic unit. The incidence of PLPH was low, occurring in only 8 patients (2.0%), the severity was mild, and the duration was less than 2 days in all cases but one. The reasons for this low frequency of PLPH in patients with dementia disorders may include disease- and/or age-related low pain sensitivity, rigid dural fibres and arteriosclerotic vessels, and large CSF space due to cerebral atrophy. Analysis of CSF is essential to identify secondary causes of dementia, preferentially chronic infections. The low frequency and severity of PLPH found in the present study shows that, with low risk of complications, lumbar puncture can be included in the routine clinical examination of demented patients.

Entities:  

Mesh:

Year:  1993        PMID: 8256560     DOI: 10.1111/j.1600-0404.1993.tb04221.x

Source DB:  PubMed          Journal:  Acta Neurol Scand        ISSN: 0001-6314            Impact factor:   3.209


  22 in total

Review 1.  Recent developments in pain in dementia.

Authors:  Erik Scherder; Joukje Oosterman; Dick Swaab; Keela Herr; Marcel Ooms; Miel Ribbe; Joseph Sergeant; Gisele Pickering; Fabrizio Benedetti
Journal:  BMJ       Date:  2005-02-26

Review 2.  The role of biomarkers in clinical trials for Alzheimer disease.

Authors:  Leon J Thal; Kejal Kantarci; Eric M Reiman; William E Klunk; Michael W Weiner; Henrik Zetterberg; Douglas Galasko; Domenico Praticò; Sue Griffin; Dale Schenk; Eric Siemers
Journal:  Alzheimer Dis Assoc Disord       Date:  2006 Jan-Mar       Impact factor: 2.703

3.  Use of CSF biomarkers in Alzheimer's disease clinical trials.

Authors:  K Blennow; H Zetterberg
Journal:  J Nutr Health Aging       Date:  2009-04       Impact factor: 4.075

Review 4.  Progress update: fluid and imaging biomarkers in Alzheimer's disease.

Authors:  Courtney L Sutphen; Anne M Fagan; David M Holtzman
Journal:  Biol Psychiatry       Date:  2013-09-05       Impact factor: 13.382

5.  Does CSF p-tau181 help to discriminate Alzheimer's disease from other dementias and mild cognitive impairment? A meta-analysis of the literature.

Authors:  Wei Tang; Qiong Huang; Yu-You Yao; Yan Wang; Yi-Le Wu; Zheng-Yu Wang
Journal:  J Neural Transm (Vienna)       Date:  2014-05-10       Impact factor: 3.575

6.  Safety of lumbar puncture procedures in patients with Alzheimer's disease.

Authors:  E Peskind; A Nordberg; T Darreh-Shori; H Soininen
Journal:  Curr Alzheimer Res       Date:  2009-06       Impact factor: 3.498

Review 7.  Neurochemical dementia diagnostics: assays in CSF and blood.

Authors:  Piotr Lewczuk; Joachim Hornegger; Rüdiger Zimmermann; Markus Otto; Jens Wiltfang; Johannes Kornhuber
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2008-11       Impact factor: 5.270

8.  cNEUPRO: Novel Biomarkers for Neurodegenerative Diseases.

Authors:  Philipp Spitzer; Hans Wolfgang Klafki; Kaj Blennow; Luc Buée; Hermann Esselmann; Sanna-Kaisa Herruka; Connie Jimenez; Peter Klivenyi; Piotr Lewczuk; Juan Manuel Maler; Katrin Markus; Helmut E Meyer; Chris Morris; Thorsten Müller; Markus Otto; Lucilla Parnetti; Hilkka Soininen; Susanna Schraen; Charlotte Teunissen; Laszlo Vecsei; Henrik Zetterberg; Jens Wiltfang
Journal:  Int J Alzheimers Dis       Date:  2010-09-19

9.  Cerebrospinal fluid analysis should be considered in patients with cognitive problems.

Authors:  Henrik Zetterberg; Niklas Mattsson; Kaj Blennow
Journal:  Int J Alzheimers Dis       Date:  2010-07-14

Review 10.  Total and phosphorylated tau protein as biological markers of Alzheimer's disease.

Authors:  Harald Hampel; Kaj Blennow; Leslie M Shaw; Yvonne C Hoessler; Henrik Zetterberg; John Q Trojanowski
Journal:  Exp Gerontol       Date:  2009-10-22       Impact factor: 4.032

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.